ReviewTrends in microbiology2018
Mechanisms of Hepatitis B Virus Persistence.
Review in Trends in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Vertical Transmission of Hepatitis B and C-Then and Now-A Comprehensive Literature Systematic Review.Viruses · 2025Pooled it
- The Antiviral Potential ofMolecules (Basel, Switzerland) · 2024Pooled it
- Liver Macrophages in the Pathogenesis of Viral Hepatitis.Current issues in molecular biology · 2026Review
- Spatiotemporal heterogeneity of neutrophil extracellular traps in hepatocellular carcinoma microenvironment and targeted therapy progress.Journal of translational medicine · 2026Review
- Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress.Molecular therapy. Nucleic acids · 2026Review
- Targeting the innate immune system in treating hepatitis B: prospects for functional cure.Clinical and molecular hepatology · 2026Review
- Innate immune recognition and evasion strategies of hepatitis B virus: from DNA to RNA and viral proteins.Frontiers in immunology · 2026Review
- Review
- An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection.Nature communications · 2025Article
- Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study.JHEP reports : innovation in hepatology · 2025Article
- Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis.Virology journal · 2025Article
- Bistability between acute and chronic states in a Model of Hepatitis B Virus Dynamics.Mathematical biosciences · 2025Article
- Taurochenodeoxycholic acid as a sensitive stratification marker for HBV-associated hepatic cirrhosis status has a hepatoprotective effect.Scientific reports · 2025Article
- Hepatocyte-intrinsic innate immunity in hepatitis B virus infection: A focused review.World journal of hepatology · 2025Review
- Maternal β-carotene supplementation improves offspring growth, development, immunity, and intestinal microbiota in chickens via immune-mediated and microbial-mediated maternal effects.Scientific reports · 2025Article
- Uncommon pulmonary manifestation of hepatitis B virus: a case report of secondary organizing pneumonia.BMC infectious diseases · 2025Article
- Epidemiological trends and projections to 2035 of hepatitis B burden in China, 1990-2021.PloS one · 2025Article
- Immunomodulatory behavior of CircRNAs in tumor microenvironment.Oncology research · 2025Review
- Evaluation of genotype characteristics and drug resistance mutations in patients with chronic hepatitis B.Scientific reports · 2024Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis B virus (HBV) chronically infects 250 million people worldwide, resulting in nearly one million deaths annually. Studies in recent years have significantly improved our knowledge on the mechanisms of HBV persistence. HBV uses multiple pathways to harness host innate immunity to enhance its replication. It can also take advantage of the developing immune system and the not-yet-stabilized gut microbiota of young children to facilitate its persistence, and use maternal viral e antigen to educate immunity of the offspring to support its persistence after vertical transmission. The knowledge gained from these recent studies paves the way for the development of new therapies for the treatment of chronic HBV infection, which has so far been very challenging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.